Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14279/22937
Title: | p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication: In silico predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein |
Authors: | Panagiotopoulos, Athanasios Tseliou, Melpomeni Karakasiliotis, Ioannis Kotzampasi, Danai Maria Daskalakis, Vangelis Kesesidis, Nikolaos Notas, George Lionis, Christos D. Kampa, Marilena Pirintsos, Stergios Sourvinos, George Castanas, Elias |
Major Field of Science: | Natural Sciences |
Field Category: | Biological Sciences |
Keywords: | Ebola;SARS-CoV-2;Importin A;Influenza A;Nucleocapsid protein;Nucleoprotein;p-cymene;Rabies |
Issue Date: | Aug-2021 |
Source: | Pharmacology Research & Perspectives, 2021, vol. 9, no. 4, articl. no. e00798 |
Volume: | 9 |
Issue: | 4 |
Journal: | Pharmacology Research & Perspectives |
Abstract: | Therapeutic regimens for the COVID-19 pandemics remain unmet. In this line, repurposing of existing drugs against known or predicted SARS-CoV-2 protein actions have been advanced, while natural products have also been tested. Here, we propose that p-cymene, a natural monoterpene, can act as a potential novel agent for the treatment of SARS-CoV-2-induced COVID-19 and other RNA-virus-induced diseases (influenza, rabies, Ebola). We show by extensive molecular simulations that SARS-CoV-2 C-terminal structured domain contains a nuclear localization signal (NLS), like SARS-CoV, on which p-cymene binds with low micromolar affinity, impairing nuclear translocation of this protein and inhibiting viral replication, as verified by preliminary in vitro experiments. A similar mechanism may occur in other RNA-viruses (influenza, rabies and Ebola), also verified in vitro for influenza, by interaction of p-cymene with viral nucleoproteins, and structural modification of their NLS site, weakening its interaction with importin A. This common mechanism of action renders therefore p-cymene as a possible antiviral, alone, or in combination with other agents, in a broad spectrum of RNA viruses, from SARS-CoV-2 to influenza A infections. |
URI: | https://hdl.handle.net/20.500.14279/22937 |
ISSN: | 20521707 |
DOI: | 10.1002/prp2.798 |
Rights: | © The Authors. This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License. Attribution-NonCommercial-NoDerivatives 4.0 International |
Type: | Article |
Affiliation : | University of Crete Democritus University of Thrace Cyprus University of Technology Nature Crete Pharmaceuticals |
Publication Type: | Peer Reviewed |
Appears in Collections: | Άρθρα/Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
prp2.798.pdf | Fulltext | 1.67 MB | Adobe PDF | View/Open |
CORE Recommender
This item is licensed under a Creative Commons License